MicroRNA‑2053 overexpression inhibits the development and progression of hepatocellular carcinoma

Song,Tao; Ma,Ke; Zhao,Cui; Yang,Jijin; Liu,Jingyu

doi:10.3892/ol.2019.10501

MicroRNA‑2053 overexpression inhibits the development and progression of hepatocellular carcinoma

Authors:
- Tao Song
- Ke Ma
- Cui Zhao
- Jijin Yang
- Jingyu Liu
View Affiliations

Affiliations: Department of Medical Imaging, Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai 200433, P.R. China, Shandong Co‑Innovation Center of Classic TCM Formula, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China, Department of General Medicine, Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China, Department of Interventional Radiology, Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai 200433, P.R. China
Published online on: June 20, 2019 https://doi.org/10.3892/ol.2019.10501
Pages: 2043-2049

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) represent a class of small RNAs that participate in the regulation of tumor progression. However, the identification of functional miRNAs in tumors has not been thoroughly elucidated. In the present study we aim to investigate the impact of altered miR‑2053 expression in hepatocellular carcinoma (HCC) cells. The results of the present study demonstrated that miR‑2053 overexpression inhibited cell proliferation, migration and invasion, and promoted apoptosis in a HCC cell line, while miR‑2053 knockdown induced the opposite cellular phenotypic changes. Mechanistically, it was found that overexpression of miR‑2053 resulted in the downregulation of the phosphoinositide 3‑kinase (PI3K) and Wnt/β‑catenin signaling pathways, which are aberrantly expressed in HCC. Collectively, the results indicate that miR‑2053 serves as a tumor suppressor with a crucial role in inhibiting the proliferation, migration and invasion of HCC via targeting the PI3K and Wnt/β‑catenin signaling pathways. These data indicate a potential application of miR‑2053 in cancer therapy.

View Figures

View References

1	Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK and Goldstein RM: Hepatocellular carcinoma: Management of an increasingly common problem. Proc (Bayl Univ Med Cent). 21:266–280. 2008. View Article : Google Scholar : PubMed/NCBI
2	Di Pardo BJ, Bronson NW, Diggs BS, Thomas CR Jr, Hunter JG and Dolan JP: The global burden of esophageal cancer: A disability-adjusted life-year approach. World J Surg. 40:395–401. 2016. View Article : Google Scholar : PubMed/NCBI
3	Yang J, Yan L and Wang W: Current status of multimodal & combination therapy for hepatocellular carcinoma. Indian J Med Res. 136:391–403. 2012.PubMed/NCBI
4	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
5	Felekkis K, Touvana E, Stefanou C and Deltas C: MicroRNAs: A newly described class of encoded molecules that play a role in health and disease. Hippokratia. 14:236–240. 2010.PubMed/NCBI
6	Wahid F, Shehzad A, Khan T and Kim YY: MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 1803:1231–1243. 2010. View Article : Google Scholar : PubMed/NCBI
7	Mott JL: MicroRNAs involved in tumor suppressor and oncogene pathways: Implications for hepatobiliary neoplasia. Hepatology. 50:630–637. 2009. View Article : Google Scholar : PubMed/NCBI
8	Fendler A, Stephan C, Yousef GM and Jung K: MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem. 57:954–968. 2011. View Article : Google Scholar : PubMed/NCBI
9	Roy S, Benz F, Luedde T and Roderburg C: The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis. Hepatobiliary Surg Nutr. 4:24–33. 2015.PubMed/NCBI
10	Szabo G and Bala S: MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 10:542–552. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hsu SH and Ghoshal K: MicroRNAs in liver health and disease. Curr Pathobiol Rep. 1:53–62. 2013. View Article : Google Scholar : PubMed/NCBI
12	Pandey R, Jackson L, Ma G and Ahmed RP: Identification of MicroRNAs inducing adult cardiomyocyte proliferation. Circulation. 130:A163142014.
13	Tsai WL and Chung RT: Viral hepatocarcinogenesis. Oncogene. 29:2309–2324. 2010. View Article : Google Scholar : PubMed/NCBI
14	Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
15	Galuppo R, Ramaiah D, Ponte OM and Gedaly R: Molecular therapies in hepatocellular carcinoma: What can we target? Dig Dis Sci. 59:1688–1697. 2014. View Article : Google Scholar : PubMed/NCBI
16	Vilchez V, Turcios L, Marti F and Gedaly R: Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
17	Qu C, He, Lu X, Dong L, Zhu Y, Zhao Q, Jiang X, Chang P, Jiang X, Wang L, et al: Salt-inducible Kinase (SIK1) regulates HCC progression and WNT/beta-catenin activation. J Hepatol. 64:1076–1089. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chu Y, Fan W, Guo W, Zhang Y, Wang L, Guo L, Duan X, Wei J and Xu G: MiR-1247-5p functions as a tumor suppressor in human hepatocellular carcinoma by targeting Wnt3. Oncol Rep. 38:343–351. 2017. View Article : Google Scholar : PubMed/NCBI
19	Yu Z, Wang Z, Li F, Yang J and Tang L: MiR-138 modulates prostate cancer cell invasion and migration via Wnt/β-catenin pathway. Mol Med Rep. 17:3140–3145. 2018.PubMed/NCBI
20	Tanabe H, Hayashi M, Sugimoto H, Kurimoto K, Hirabayashi S, Kanda M, Takami H, Niwa Y, Iwata N, Kobayashi D, et al: Abstract 3429: Oncogenic function of miR-23b-3p in hepatocellular carcinoma. Cancer Res. 77:3429. 2017.
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Fritz V and Fajas L: Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene. 29:4369–4377. 2010. View Article : Google Scholar : PubMed/NCBI
23	Curran S and Murray GI: Matrix metalloproteinases in tumor invasion and metastasis. J Pathol. 189:300–308. 1999. View Article : Google Scholar : PubMed/NCBI
24	Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T and Van Dyke T: p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:703–711. 1994. View Article : Google Scholar : PubMed/NCBI
25	Martinou JC and Youle R: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
26	Gui D, Guo Y, Wang F, Liu W, Chen J, Chen Y, Huang J and Wang N: Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One. 7:e398242012. View Article : Google Scholar : PubMed/NCBI
27	Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 39:177–186. 2010. View Article : Google Scholar
28	Tuo H, Wang Y, Wang L, Yao B, Li Q, Wang C, Liu Z, Han S, Yin G, Tu K and Liu Q: MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/β-catenin pathway in hepatocellular carcinoma. Oncotarget. 8:65687–65698. 2017. View Article : Google Scholar : PubMed/NCBI
29	Cao N, Mu L, Yang W, Liu L, Liang L and Zhang H: MicroRNA-298 represses hepatocellular carcinoma progression by inhibiting CTNND1-mediated Wnt/β-catenin signaling. Biomed Pharmacother. 106:483–490. 2018. View Article : Google Scholar : PubMed/NCBI
30	Balogh J, Victor D III, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma. 3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
31	Chu R, Mo G, Duan Z, Huang M, Chang J, Li X and Liu P: MiRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 12:452014. View Article : Google Scholar : PubMed/NCBI
32	Thurnherr T, Mah WC, Lei Z, Jin Y, Rozen SG and Lee CG: Differentially expressed miRNAs in hepatocellular carcinoma target genes in the genetic information processing and metabolism pathways. Sci Rep. 6:200652016. View Article : Google Scholar : PubMed/NCBI
33	Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T and Schmittgen TD: MiR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 71:7608–7616. 2011. View Article : Google Scholar : PubMed/NCBI
34	Zhang JG, Shi Y, Hong DF, Song M, Huang D, Wang CY and Zhao G: MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/beta-catenin pathway. Sci Rep. 5:80872015. View Article : Google Scholar : PubMed/NCBI
35	Liu K, Li X, Cao Y, Ge Y, Wang J and Shi B: MiR-132 inhibits cell proliferation, invasion and migration of hepatocellular carcinoma by targeting PIK3R3. Int J Oncol. 47:1585–1593. 2015. View Article : Google Scholar : PubMed/NCBI
36	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
37	Tu K, Liu Z, Yao B, Han S and Yang W: MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974. 2016. View Article : Google Scholar : PubMed/NCBI
38	Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
39	Gao N, Zhang Z, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003. View Article : Google Scholar : PubMed/NCBI
40	Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P and Wands JR: Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 48:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
41	Jiang J, Yu C, Chen M, Tian S and Sun C: Over-expression of TRIM37 promotes cell migration and metastasis in hepatocellular carcinoma by activating Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 464:1120–1127. 2015. View Article : Google Scholar : PubMed/NCBI
42	Juan S, Anling Z, Zhendong S, Ma F, Pu P, Wang T, Zhang J, Kang C and Zhang Q: MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin. Int J Oncol. 40:1162–1170. 2012.PubMed/NCBI